#174: The Story of Tessera Therapeutics with CEO and co-founder Geoff von Maltzahn 🥼

from The Healthtech Podcast · host Dr. James Somauroo

This week, James is joined by Geoff von Maltzahn, CEO and co-founder at Tessera Therapeutics. Tessera is an early-stage biotech start-up that launched this summer with $50M in financing to pioneer a new category in ‘gene writing.’ Going even further than CRISPR, Tessera’s gene writing technology presents the potential to cure genetic disorders, cancers, and even infectious diseases like COVID-19. Geoffrey was awarded a Ph.D. in biomedical engineering and medical physics from MIT. Get in touch with Geoff: @GVMaltzahn | https://www.linkedin.com/in/geoffrey-von-maltzahn-7a6b755a/ Subscribe to Healthtech Pigeon 🐦www.healthtechpigeon.com Get in touch: www.jamessomauroo.com | www.somx.co.uk

Episode metadata supplied by the publisher feed · Published Feb 18, 2021

Embed this episode

Attribution link and audio player

Ready to play

#174: The Story of Tessera Therapeutics with CEO and co-founder Geoff von Maltzahn 🥼

0:00 45:49

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Healthtech Podcast?

This episode is 45 minutes long.

When was this The Healthtech Podcast episode published?

This episode was published on February 18, 2021.

Can I download this The Healthtech Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!